Mismatch repair deficiency in ovarian cancer - Molecular characteristics and clinical implications

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 506-512

  Xiao, Xue ^a   Melton, David W ^a   Gourley, Charlie ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

HNPCC; Mismatch repair deficiency; Ovarian cancer; Synthetic lethality

Indexed keywords

HNPCC; MISMATCH REPAIR DEFICIENCY; OVARIAN CANCER; SYNTHETIC LETHALITY;

DNA MISMATCH REPAIR; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84894024812     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.003     Document Type: Review

References (70)

1. NCI National Cancer Institute (NCI), Cancer Statistics > Cancer Stat Fact Sheets > Cancer of the Ovary Available from: http://seer.cancer.gov/ statfacts/html/ovary.html 2012
2. A. Bashashati et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling J Pathol 231 1 2013 21 34
3. N. Colombo et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v23 v30
4. C.M. Conklin, and C.B. Gilks Differential diagnosis and clinical relevance of ovarian carcinoma subtypes Expert Rev Obstet Gynecol 8 1 2013 67 82
5. M. Köbel et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas Int J Gynecol Pathol 29 3 2010 203 211
6. N. Lalwani et al. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment Radiographics 31 3 2011 625 646
7. J.D. Seidman et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin Int J Gynecol Pathol 23 1 2004 41 44
8. C.H. Holschneider, and J.S. Berek Ovarian cancer: epidemiology, biology, and prognostic factors Seminars in surgical oncology 2000 Wiley Online Library
9. K. Alsop et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation - positive women with ovarian cancer: a report from the Australian ovarian cancer study group J Clin Oncol 30 21 2012 2654 2663
10. H.A. Risch et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 23 2006 1694 1706
11. K.A. Schrader et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy Obstet Gynecol 120 2, Part 1 2012 235 240
12. C.A. Bandera Advances in the understanding of risk factors for ovarian cancer J Reprod Med 50 6 2005 399 406
13. C. Bewtra, P. Watson, T. Conway, C. Read-Hippee, and H.T. Lynch Hereditary ovarian cancer: a clinicopathological study Int J Gynecol Pathol 11 3 1992 180
14. S. Malander et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer Gynecol Oncol 101 2 2006 238 243
15. S.C. Rubin et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing Am J Obstet Gynecol 178 4 1998 670 677
16. H.T. Lynch, M.J. Casey, J. Lynch, T.E. White, and A.K. Godwin Genetics and ovarian carcinoma Semin Oncol 25 3 1998 265 280
17. G.M. Li Mechanisms and functions of DNA mismatch repair Cell Res 18 1 2008 85 98
18. P. Macpherson et al. 8-Oxoguanine incorporation into DNA repeats in vitro and mismatch recognition by MutSα Nucleic Acids Res 33 16 2005 5094 5105
19. T. Pal, J. Permuth-Wey, and T.A. Sellers A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer Cancer 113 4 2008 733 742
20. J. Genschel, S.J. Littman, J.T. Drummond, and P. Modrich Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha J Biol Chem 273 31 1998 19895 19901
21. P. Modrich Mechanisms in eukaryotic mismatch repair J Biol Chem 281 41 2006 30305 30309
22. F.A. Kadyrov, L. Dzantiev, N. Constantin, and P. Modrich Endonucleolytic function of MutLα in human mismatch repair Cell 126 2 2006 297 308
23. L. Gu, Y. Hong, S. McCulloch, H. Watanabe, and G.M. Li ATP-dependent interaction of human mismatch repair proteins and dual role of PCNA in mismatch repair Nucleic Acids Res 26 5 1998 1173 1178
24. P. Hsieh, and K. Yamane DNA mismatch repair: molecular mechanism, cancer, and ageing Mech Ageing Dev 129 7 2008 391 407
25. M. Seifert, and J. Reichrath The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer J Mol Histol 37 5 2006 301 307
26. W.M. Abdel-Rahman, J.P. Mecklin, and P. Peltomäki The genetics of HNPCC: application to diagnosis and screening Crit Rev Oncol Hematol 58 3 2006 208 220
27. C.R. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 22 1998 5248 5257
28. P.D. Turnpenny, and S. Ellard Emery's elements of medical genetics 2011 Churchill Livingstone
29. S.M. Woerner et al. Microsatellite instability of selective target genes in HNPCC-associated colon adenomas Oncogene 24 15 2005 2525 2535
30. K. Imai, and H. Yamamoto Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics Carcinogenesis 29 4 2008 673 680
31. C. Shannon et al. Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium Clin Cancer Res 9 4 2003 1387 1392
32. A.G. Knudson Jr. Mutation and cancer: statistical study of retinoblastoma Proc Natl Acad Sci U S A 68 4 1971 820 823
33. E. Gras et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors Cancer 92 11 2001 2829 2836
34. S.A. Wajed, P.W. Laird, and T.R. DeMeester DNA methylation: an alternative pathway to cancer Ann Surg 234 1 2001 10
35. M. Aarnio, J.P. Mecklin, L.A. Aaltonen, M. Nyström-Lahti, and H.J. Järvinen Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome Int J Cancer 64 6 1995 430 433
36. H.T. Lynch et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management Mol Oncol 3 2 2009 97 137
37. K. Domanska, S. Malander, A. Måsbäck, and M. Nilbert Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40 Int J Gynecol Cancer 17 4 2007 789 793
38. T. Pal et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer Br J Cancer 107 10 2012 1783 1790
39. K.Q. Cai et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma Hum Pathol 35 5 2004 552 559
40. L. Catasús et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas Hum Pathol 35 11 2004 1360 1368
41. K.C. Jensen et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger Am J Surg Pathol 32 7 2008 1029
42. Y. Watanabe, M. Koi, H. Hemmi, H. Hoshai, and K. Noda A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer Br J Cancer 85 7 2001 1064
43. D.G. Rosen, K.Q. Cai, R. Luthra, and J. Liu Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma Mod Pathol 19 11 2006 1414 1420
44. H. UEDA et al. Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma Anticancer Res 25 4 2005 2785 2788
45. J. Liu et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer Mod Pathol 17 1 2004 75 80
46. J.P. Geisler et al. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma Cancer 98 10 2003 2199 2206
47. J. Helleman et al. Mismatch repair and treatment resistance in ovarian cancer BMC Cancer 6 1 2006 201
48. S. Popat, R. Hubner, and R. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 3 2005 609 618
49. M. Radman, and R. Wagner Carcinogenesis. Missing mismatch repair Nature 366 6457 1993 722
50. T.E.M. Crijnen et al. Survival of patients with ovarian cancer due to a mismatch repair defect Fam Cancer 4 4 2005 301 305
51. M. Scartozzi et al. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients Eur J Cancer 39 8 2003 1144 1149
52. E.M. Grindedal et al. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds J Med Genet 47 2 2010 99 102
53. Z. Kemp, and J. Ledermann Update on first-line treatment of advanced ovarian carcinoma Int J Women's Health 5 2013 45 51
54. G. Strathdee, M.J. MacKean, M. Illand, and R. Brown A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer Oncogene 18 14 1999 2335
55. C. Zeller et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling Oncogene 31 42 2012 4567 4576
56. J.A. Plumb, G. Strathdee, J. Sludden, S.B. Kaye, and R. Brown Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter Cancer Res 60 21 2000 6039 6044
57. A. Ercoli et al. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer Br J Cancer 80 10 1999 1665
58. C.L. Marcelis, H.W. van der Putten, C. Tops, L.C. Lutgens, and U. Moog Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation? Fam Cancer 1 2 2001 107 109
59. G. Samimi et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy Clin Cancer Res 6 4 2000 1415 1421
60. C.L. Tucker, and S. Fields Lethal combinations Nat Genet 35 3 2003 204 205
61. H.E. Bryant et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase Nature 434 7035 2005 913 917
62. H. Farmer et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 7035 2005 917 921
63. S.A. Martin, M. Hewish, D. Sims, C.J. Lord, and A. Ashworth Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers Cancer Res 71 5 2011 1836 1848
64. S.A. Martin et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Cancer Cell 17 3 2010 235 248
65. S.A. Martin et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 EMBO Mol Med 1 6-7 2009 323 337
66. Q.J. Zhai, D.G. Rosen, K. Lu, and J. Liu Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific Int J Clin Exp Pathol 1 6 2008 502 509
67. A. Aysal et al. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability Am J Surg Pathol 36 2 2012 163 172
68. D. Coppola et al. Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer Anticancer Res 32 11 2012 4963 4969
69. G. Strathdee et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes Am J Pathol 158 3 2001 1121
70. J. Willner et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types Hum Pathol 38 4 2007 607 613